Gold tier: mechanically validated evidence, with its primary source.
709 evidence items · page 11 / 29
9 %Twenty-one (9%) of 230 patients in the efavirenz group experienced HIV-associated non-AIDS illnesses.
Côte d'IvoireHIV-associated non-AIDS illnessespublished 2021The Lancet. Infectious diseaseseurope_pmcdocument of 11 observationsDOI 10.1016/s1473-3099(20)30869-0
0 seroconversionsNo HIV and HBV seroconversion was observed after a 3-month follow-up among rape victims receiving antiretroviral chemoprophylaxis in Abidjan.
Côte d'Ivoirehépatite B · VIH/sidapublished 2015Medecine et maladies infectieuseseurope_pmcdocument of 3 observations
4.2 %Among the 943 inmates screened at the Correctional and Detention Facility of Abidjan, 40 (4.2%) had probable pulmonary TB.
Côte d'Ivoirepulmonary TBobserved 2015published 2017PloS oneeurope_pmcdocument of 8 observations
17.9 %Cerebral toxoplasmosis accounted for 17.9% of AIDS-defining reasons for hospitalization.
Côte d'Ivoirecerebral toxoplasmosis · VIH/sidapublished 2013Bulletin de la Societe de pathologie exotique (1990)europe_pmcdocument of 16 observations
7.6 %The overall prevalence of severe cardiovascular abnormalities (SCA) in the study population was 7.6%.
Côte d'Ivoiresevere cardiovascular abnormalitiesobserved 2015published 2021Southern African journal of infectious diseaseseurope_pmcdocument of 9 observationsDOI 10.4102/sajid.v36i1.187
8.6 %8.6% of patients interrupted antiretroviral chemoprophylaxis treatment.
Côte d'IvoireVIH/sidaobserved 2000-2007published 2010Medecine et maladies infectieuseseurope_pmcdocument of 13 observations
21.49 %Malaria case prevalence in the LLIN plus Bti group was 21.49% (570/2652) pre-intervention.
Côte d'IvoirepaludismeHAL · Unilimdocument of 54 observations
0.5 per_100_person_weeksMalaria incidence rates remained below 0.5 cases per 100 person-weeks in the 5–18-year-old age group.
Côte d'IvoirepaludismeHAL · Unilimdocument of 122 observations
22.9 %Tuberculosis accounted for 22.9% of causes of death.
Côte d'Ivoiretuberculosepublished 2013Bulletin de la Societe de pathologie exotique (1990)europe_pmcdocument of 16 observations
Avascular osteonecrosis of the femoral head was diagnosed in all three patients, with unilateral involvement in two and bilateral involvement in one.
Côte d'Ivoireavascular osteonecrosis of the femoral headpublished 2009Antiviral therapyeurope_pmcdocument of 11 observations
86 cells/mm³CD4(+) T-cell nadirs were 86 cells/mm³, 99 cells/mm³, and 12 cells/mm³ for the three patients.
Côte d'IvoireVIH/sidapublished 2009Antiviral therapyeurope_pmcdocument of 11 observations
13 patients13 patients had been treated (21%).
Côte d'IvoireVIH/sidaobserved 1999–2006published 2010Le Mali medicaleurope_pmcdocument of 17 observations
87 %At month 6, 87% of HIV-1-infected adults on zidovudine + lamivudine + efavirenz had undetectable viral load.
Côte d'IvoireVIH/sidaobserved month 6published 2006Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 9 observationsDOI 10.1097/01.qai.0000219777.04927.50
75 %At month 24 after ART initiation, 75% of patients with detectable viral loads had resistant virus.
Côte d'IvoireVIH/sidapublished 2013Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 11 observations
186 per_mm3The median pre-antiretroviral treatment CD4 count was 186 per mm³.
Côte d'IvoireVIH/sidapublished 2013BMC infectious diseaseseurope_pmcdocument of 10 observationsDOI 10.1186/1471-2334-13-607
77.3 %Among 130 patients who reported a relevant clinical indicator, 92 (77.3%) experienced at least one missed opportunity for HIV testing.
Côte d'IvoireVIH/sidaobserved 2013–2014published 2017PloS oneeurope_pmcdocument of 5 observations
4.7 %HIV prevalence was 4.7% in the referent group of 442 patients.
Côte d'IvoireVIH/sidapublished 2012PloS oneeurope_pmcdocument of 7 observationsDOI 10.1371/journal.pone.0048108
4 %The Senegal haplotype was detected in 4% of the samples.
Côte d'Ivoirehemoglobin disordersHAL · Unilimdocument of 23 observations
17.25 yearsDiscounted life expectancy was 17.25 years for adaptive viral load monitoring.
Côte d'IvoireVIH/sidapublished 2016Clinical infectious diseases : an official publication of the Infectious Diseases Society europe_pmcdocument of 5 observations
1.9 %HIV prevalence in the West and Central African region is 1.9%.
Côte d'IvoireVIH/sidapublished 2020International journal of infectious diseases : IJID : official publication of the Internateurope_pmcdocument of 3 observations
0 %Cumulative proportion of HBsAg seroclearance was 0% in patients with baseline pcG1896A mutation and 36.9% in those without, among antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire.
Côte d'Ivoirehépatite Bpublished 2018Journal of viral hepatitiseurope_pmcdocument of 7 observationsDOI 10.1111/jvh.12914
78 %The median self-reported adherence rate to highly active antiretroviral therapy (HAART) was 78% among HIV-infected adults followed in field conditions in Abidjan.
Côte d'IvoireVIH/sidapublished 2007Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 2 observationsDOI 10.1097/qai.0b013e31805d8ad0
11 casesOf the 1023 HIV-1-infected adults randomized in the Temprano deferred-ART group, 11 (1.1%) were viremic controllers.
Côte d'IvoireVIH/sidapublished 2022AIDS (London, England)europe_pmcdocument of 3 observations
59.3 %Baseline pcG1896A mutation was identified in 51 (59.3%) of 86 antiretroviral-naïve HIV-HBV co-infected patients from Côte d'Ivoire.
Côte d'Ivoirehépatite Bpublished 2018Journal of viral hepatitiseurope_pmcdocument of 7 observationsDOI 10.1111/jvh.12914
6.8 %Among the 2056 patients, 6.8% were obese at baseline.
Côte d'Ivoireobésitépublished 2017PloS oneeurope_pmcdocument of 8 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.